37 / 154
A B S T R A C T S
S7
S19
NORTH AMERICA
Arti Hurria
Medical Oncology, Duarte, United States of America
This plenary session will focus on geriatric oncology
multidisciplinary models of care in North America. Three
multidisciplinary models of geriatric oncology care will
be highlighted. The first is a consultative model, in which
patients are referred to a geriatric oncology clinic for a
geriatric assessment and recommendations. This assessment
is often performed in collaboration with a multidisciplinary
team. The results of this consultation are conveyed to the
treating oncologist with a summary of findings from the
geriatric assessment, which can then be utilized to guide
interventions. The second is a shared care model in which
the geriatrician or geriatric oncologist and multidisciplinary
team provide concurrent collaborative care with the primary
treating oncologist across the trajectory of the patient’s
illness. The third is a comprehensive care model where the
patient is specifically referred to a geriatric oncologist who
is the treating oncologist throughout the patient’s trajectory
of care. Members of the multidisciplinary team are consulted
and provide collaborative care. Each of these models provides
a unique service; however, there are pros and cons to each
approach which will be discussed during this lecture.
Disclosure of interest:
Researchsupport: Celegene,Novartis,
and GSK. Consultant: Boehringer Ingelheim Pharmaceuticals,
Carevive, Sanofi, and GTx, Inc.
S20
SIOG TASK FORCE FOR METASTATIC RCC IN THE ELDERLY
2016
Ravindran Kanesvaran
National Cancer Centre Singapore, Medical Oncology, Singapore,
Singapore
Treatment of metastatic renal cell carcinoma (mRCC)
has evolved tremendously over the past decade since the
advent of targeted therapies. In line with this, SIOG had
established a task force in 2008 to come up with treatment
recommendations for the elderly mRCC patient, an important
group that has often been overlooked in terms of recruitment
into clinical trials. In that guideline which was published in a
high impact journal in 2009, the task force not only analyzed
the evidence regarding the state of art management in mRCC
in the elderly but was also able to apply that knowledge
by taking into consideration factors unique to an elderly
population. These factors include physiological, pathological,
pharmacological, and psychological factors that distinguish
the older mRCC patients from those younger. It has been
6 years since the publication of the above position paper
and the treatment landscape has changed a lot since. Since
the 2009 paper a slew of new drugs like Pazopanib , Axitinib,
Cabozantinib, Nivolumab, and Lenvatinib have been approved
for mRCC treatment. Quality of life improvement and patient
preference studies have also changed our practice patterns.
We also have more data now regarding how these drugs
work in the elderly population too. Hence a SIOG Task Force
for treatment of mRCC in the elderly was formed to review
current data and suggest treatment for this group of patients.
Disclosure of interest:
Consultant/Honoraria: Novartis,
Pfizer, MSD, BMS
S21
Ravindran Kanesvaran
National Cancer Centre Singapore, Medical Oncology, Singapore,
Singapore
The speaker abstract has not been received at the time of
publication.
S22
GERIATRIC ONCOLOGY PROJECTION IN THE MIDDLE-EAST:
FINDINGS FROM LEBANON 2003–2023
Joseph Kattan
Chair, Hematology-Oncology, Beirut, Lebanon
Introduction:
Age is a major non-preventable risk factor for
cancer with an increase in the incidence of cancer among the
elderly. In Lebanon, the increased burden of cancer linked to
aging has not been consistently assessed at the national level.
The purpose of this study is to provide projections of cancer
incidence rates for men and women in the age groups 65–69,
70–74 and 75 years and above, from 2003 to 2023.
Material and methods:
Incidence rates per 100,000 for the
major cancer types were derived from the national cancer
registry from 2003 to 2008 among elderly patients aged
65 years and above. The six consecutive years surveys results
were used to project the incidence until 2023 using a linear
model. The variation of trends whether an increase, decrease
or stability was assessed by calculating the annual percent
change.
Results:
For males, cancer incidence rates are estimated to
rise between 2003 and 2023 from 647.2 per 100 000 to 2566.4
and from 431.5 to 4661.9 in individuals aged 65–69 and 70–74
respectively; while it remained stable in patients aged 75 and
above ranging from 1682.8 to 1615 between 2003 and 2023.
Prostate cancer was the most diagnosed cancer in males and
had his incidence increase in the 65–69 and 70–74 age groups
from 158.4 to 623.3 and from 105.6 to 1110 respectively; while
it decreased from 424.9 to 373.3 in patients aged 75 and above.
This trend was also observed in bladder and lung cancer,
the most frequent types after prostate. In females, cancer
incidence is estimated to increase from 434.3 to 2025 and from
289.5 to 3141.3 between 2003 and 2023 in the subgroups 65–69
and 70–74 years respectively; however, it remained stable in
the subgroup 75 and above ranging from 1078.5 per 100 000